Exchange: NASDAQ·Updated 06:52 PM EST

ENGN News

News
all
press releases
enGene Therapeutics Inc. (ENGN) Presents at UBS Global Biopharma Conference 2026 Transcript
enGene Therapeutics Inc. (ENGN) Presents at UBS Global Biopharma Conference 2026 Transcript...
SeekingAlpha
enGene Therapeutics Inc. (ENGN) Presents at UBS Global Biopharma Conference 2026 Transcript
enGene Therapeutics Inc. (ENGN) Presents at UBS Global Biopharma Conference 2026 Transcript...
SeekingAlpha
More News
Ainos (NASDAQ:AIMD), NeOnc Technologies Holdings (NASDAQ:NTHI), enGene Therapeutics (NASDAQ:ENGN), CuriosityStream (NASDAQ:CURI), Tecogen (NYSEAMERICAN:TGEN) and Exascale Labs Holdings (NASDAQ:XLAB) are offering compelling narratives.
24-7 Market News
enGene Therapeutics Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company, today announced updated results from the pivotal Cohort 1 of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene). Data from Cohort 1, which...
Business Wire
enGene Therapeutics Inc. (Nasdaq: ENGN) (enGene or the Company), a clinical-stage, non-viral genetic medicines company, today announced the appointments of Erik T. Goluboff, MD, MBA as Chief Medical Officer and Jason Duncan as Chief Legal and Administrative Officer, effective November 9, 2026...
Business Wire
enGene Therapeutics Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences: UBS Global Biopharma Conference 2026 Date: Monday, November 16, 2026 Time: 3:20 p.m. GMT...
Business Wire
enGene Therapeutics Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company, today announced that it will host a webinar on Thursday, October 15, 2026 at 10:00 AM ET that will provide greater detail on the preclinical data supporting the incorporation of...
Business Wire
(RTTNews) - enGene Therapeutics Inc. (ENGN) released a profit for third quarter of $32.50 million...
Nasdaq News: Markets
enGene Therapeutics Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter ended July 31, 2026, and provided clinical and corporate updates. As we move through the second half of 2026, our focus...
Business Wire
enGene Therapeutics Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Date: Tuesday, September 8, 2026 Time: 10:15...
Business Wire
enGene Therapeutics Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, August 11, 2026 at 11:00 AM ET featuring Neal Shore, MD, FACS (Carolina Urologic Research...
Business Wire

Advertisement|Remove ads.